 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | Lungfit BRO (nitric oxide) / Beyond Air, Inomax (nitric oxide) / Mallinckrodt
Journal: Evaluation of Inhaled Nitric Oxide Generation Systems at Altitude. (Pubmed Central) - Aug 20, 2024
Altitude significantly affected INO delivery accuracy at 14,000?ft (4,267?meter) (P??0.05) although there were large variations with selected ventilator settings. With careful monitoring, devices creating INO from room air without cylinders could be used during aeromedical transport without the need for pressurized cylinders.
- || Lungfit BRO (nitric oxide) / Beyond Air
Clinical, Journal: A safety evaluation of intermittent high-dose inhaled nitric oxide in viral pneumonia due to COVID-19: a randomised clinical study. (Pubmed Central) - Jul 31, 2024
With careful monitoring, devices creating INO from room air without cylinders could be used during aeromedical transport without the need for pressurized cylinders. Among the Treatment-Group, oxygen support duration was reduced by 2.7
- ||| Lungfit BRO (nitric oxide) / Beyond Air
Trial completion, Trial completion date, Trial primary completion date, Nontuberculous mycobacteria: A Pilot Study to Assess the Effect of Intermittent iNO on the Treatment of NTM Lung Infection in CF and Non-CF Patients (clinicaltrials.gov) - Dec 16, 2022
P=N/A, N=15, Completed, Sponsor: Beyond Air Inc.
Among the Treatment-Group, oxygen support duration was reduced by 2.7 Recruiting --> Completed | Trial completion date: May 2022 --> Oct 2022 | Trial primary completion date: Dec 2021 --> Jul 2022
- ||| Lungfit BRO (nitric oxide) / Beyond Air
Trial completion, Enrollment change: Inhaled NO for the Treatment of Viral Pneumonia in Adults (clinicaltrials.gov) - Dec 16, 2022
P=N/A, N=40, Completed, Sponsor: Beyond Air Inc.
Recruiting --> Completed | Trial completion date: May 2022 --> Oct 2022 | Trial primary completion date: Dec 2021 --> Jul 2022 Recruiting --> Completed | N=90 --> 40
- | Lungfit BRO (nitric oxide) / Beyond Air
Journal: Inhaled Nitric Oxide for the Treatment of Acute Bronchiolitis: A Multicenter Randomized Controlled Trial to Evaluate Dose Response. (Pubmed Central) - Sep 29, 2022
Treatment with high dose intermittent iNO at 150 ppm showed reduced time to clinical improvement when compared to 85 ppm or control treatment of hospitalized infants with acute bronchiolitis. The 150 ppm iNO dose is well-tolerated, with significant benefit compared to both standard therapy and 85 ppm iNO, improving respiratory outcome and reducing length of stay.
- Lungfit BRO (nitric oxide) / Beyond Air
Characterization of Inhaled Nitric Oxide (iNO) for the treatment of Viral Community Acquired Pneumonia (CAP) (Virtual) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_2194;
- Lungfit BRO (nitric oxide) / Beyond Air
HOME-BASED TREATMENT OF NONTUBERCULOUS MYCOBACTERIA PULMONARY DISEASE VIA A NOVEL NITRIC OXIDE GENERATOR AND DELIVERY SYSTEM (Convention Center Exhibit Hall: Rapid Area 4D) - Aug 16, 2022 - Abstract #CHEST2022CHEST_2057;
Using the easy-to-operate and compact novel NO generator, all patients demonstrated ability to be trained to self-administer therapies at home. CLINICAL IMPLICATIONS: Beneficial outcomes of NO in NTM disease are anticipated due to its antimicrobial effects, and further clinical studies are required to establish the benefit of the treatment.
- Lungfit BRO (nitric oxide) / Beyond Air
Treatment of COVID-19 with inhaled nitric oxide using a novel nitric oxide generator () - Mar 28, 2022 - Abstract #ECCMID2022ECCMID_4052;
- Lungfit BRO (nitric oxide) / Beyond Air
Home-Based Intermittent Inhaled High-Dose Nitric Oxide in Nontuberculous Mycobacterial Pulmonary Disease Using a Novel Nitric Oxide Generator and Delivery System Is Safe and Well Tolerated (Room 207-208 (South Building, Level 2), Moscone Center) - Feb 19, 2022 - Abstract #ATS2022ATS_4125;
Overall, the intermittent high-dose NO treatment regimen has been well-tolerated in the hospital and home settings, with patients demonstrating the ability to be trained to self-administer treatments using this novel NO generation and delivery device and early improvements in QOL-B (NTM). Given the antimicrobial, anti-inflammatory, and direct pulmonary vasodilation effects of NO, beneficial effects of NO treatment on NTM lung infections are anticipated.
- || Lungfit BRO (nitric oxide) / Beyond Air
Trial completion date, Trial primary completion date: Inhaled NO for the Treatment of Viral Pneumonia in Adults (clinicaltrials.gov) - Feb 1, 2022
P=N/A, N=90, Recruiting, Sponsor: Beyond Air Inc.
Given the antimicrobial, anti-inflammatory, and direct pulmonary vasodilation effects of NO, beneficial effects of NO treatment on NTM lung infections are anticipated. Trial completion date: Sep 2021 --> Sep 2022 | Trial primary completion date: Sep 2021 --> Sep 2022
- Lungfit BRO (nitric oxide) / Beyond Air
[VIRTUAL] Efficacy and Safety of Inhaled Nitric Oxide for the Treatment of Acute Bronchiolitis: An Evaluation of Three Trials () - Mar 14, 2021 - Abstract #ATS2021ATS_4913;
The 85 ppm NO group did not demonstrate efficacy compared to the SST group. The data indicate the efficacy and safety of intermittent administration of 150 or 160 ppm iNO in the treatment of infants with acute bronchiolitis.
- Lungfit BRO (nitric oxide) / Beyond Air
[VIRTUAL] Inhaled Nitric Oxide for the Treatment of COVID-19 and Other Viral Pneumonias in Adults () - Mar 14, 2021 - Abstract #ATS2021ATS_1608;
The data indicate the efficacy and safety of intermittent administration of 150 or 160 ppm iNO in the treatment of infants with acute bronchiolitis. Based on current data demonstrating the antiviral and anti-inflammatory effects of NO, in addition to its complex beneficial effect on oxygenation, iNO delivered by the LungFit system has the potential to treat viral pneumonias including COVID-19, thereby providing therapy for this currently unmet medical need.
- ||| Lungfit BRO (nitric oxide) / Beyond Air
New trial, Nontuberculous mycobacteria: A Pilot Study to Assess the Effect of Intermittent iNO on the Treatment of NTM Lung Infection in CF and Non-CF Patients (clinicaltrials.gov) - Dec 27, 2020
P=N/A, N=20, Recruiting, Sponsor: Beyond Air Inc.
- ||| Lungfit BRO (nitric oxide) / Beyond Air
Enrollment open: Inhaled NO for the Treatment of Viral Pneumonia in Adults (clinicaltrials.gov) - Dec 3, 2020
P=N/A, N=90, Recruiting, Sponsor: Beyond Air Inc.
Based on current data demonstrating the antiviral and anti-inflammatory effects of NO, in addition to its complex beneficial effect on oxygenation, iNO delivered by the LungFit system has the potential to treat viral pneumonias including COVID-19, thereby providing therapy for this currently unmet medical need. Not yet recruiting --> Recruiting
- | Lungfit BRO (nitric oxide) / Beyond Air
New trial: Inhaled NO for the Treatment of Viral Pneumonia in Adults (clinicaltrials.gov) - Oct 27, 2020
P=N/A, N=90, Not yet recruiting, Sponsor: Beyond Air Inc.